TAK-188
Unknown / undisclosed
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1/2 (1)
What this study did
Competitive landscape
This drug's own stage for Advanced Solid Tumors: Stage not on record. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| TAK-188: this drug | Stage not on record | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| AZD4956 | Phase 1/2(overall) | Small molecule | POLQ (DNA polymerase theta) | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986517 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986548 | Phase 1/2(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-6768 | Phase 1/2 | Undisclosed | Fibroblast Activation Protein (FAP) | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-8364 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Palacaparib | Phase 1/2(overall) | Small molecule | PARP1 inhibitor (next-gen) | not yet graded | No reviewed efficacy summary in this indication | |
| REGN10597 | Phase 1/2 | Multispecific antibody | PD-1 x IL-2Rα (IL2RA) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-1681 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-4298 | Phase 1/2(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-4375 | Phase 1/2 | Antibody–drug conjugate | Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF), Tissue Factor (TF) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-4610 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-7787 | Phase 1/2 | Multispecific antibody | DLL3 (Delta-like ligand 3) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-9803 | Phase 1/2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| TAK-505 | Phase 1/2(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-253 | Phase 1 | Biologic (subtype unspecified) | c-MET | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986500 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK5533524 | Phase 1 | Antibody–drug conjugate | MUC16 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-6093 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-87890387 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-89862175 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| MP0310 | Phase 1 | Protein / enzyme therapeutic | FAP x 4-1BB (CD137) | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3821 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-4685 | Phase 1(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-4849 | Phase 1 | Antibody–drug conjugate | DLL3 | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-7782 | Phase 1(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| TAK-168 | Phase 1(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| YS-ON-001 | Phase 1 | Biologic (subtype unspecified) | TLR3 (poly I:C adjuvant) | not yet graded | No reviewed efficacy summary in this indication | |
| 225Ac-ETN029 | —(overall) | Radioligand Therapy (actinium-225) | DLL3 | not yet graded | No reviewed efficacy summary in this indication | |
| AAA614 | —(overall) | Radioligand Therapy | Fibroblast Activation Protein (FAP) | not yet graded | No reviewed efficacy summary in this indication | |
| AZD5863 | —(overall) | Multispecific antibody | Claudin 18.2 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD9793 | —(overall) | Multispecific antibody | Glypican-3 (GPC3) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| BMS-986506 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| GCJ904 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK5460025 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| PF-08032560 | —(overall) | Small molecule | KAT6A/KAT6B and KAT7 | not yet graded | No reviewed efficacy summary in this indication | |
| PF-08046044 | —(overall) | Antibody–drug conjugate | Anti-CD30 antibody-drug conjugate | not yet graded | No reviewed efficacy summary in this indication | |
| RG6505 | —(overall) | Undisclosed | RAS (pan-RAS, RAS-mutant tumors) | not yet graded | No reviewed efficacy summary in this indication | |
| RG6620 | —(overall) | Undisclosed | KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D, KRAS G12D | not yet graded | No reviewed efficacy summary in this indication | |
| RG6648 | —(overall) | Antibody–drug conjugate | c-MET | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow TAK-188 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.